All Monthly Communication Reports for Innovative Medicines Canada / Médicaments novateurs Canada

Pamela Fralick, President (Organization)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-706 of 706


  1. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Stephen Lucas, Deputy Minister | Health Canada (HC)
    • Marcel Saulnier, Associate ADM | House of Commons
    • Kendal Weber, Associate Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2020-01-29
    Posted date: 2020-02-14
    Communication number: 371-463180 View associated registration

  2. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2020-01-28
    Posted date: 2020-02-13
    Communication number: 371-464292 View associated registration

  3. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bill Morneau, Minister of Finance | Finance Canada (FIN)
    • Elder Marques, Chief of Staff to Minister Morneau | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2020-01-24
    Posted date: 2020-02-13
    Communication number: 371-464296 View associated registration

  4. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ryan Dunn, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, International Relations, Science and Technology
    Communication date: 2020-01-15
    Posted date: 2020-02-13
    Communication number: 371-464293 View associated registration

  5. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marcel Saulnier, Associate ADM | Health Canada (HC)

    Subject Matter of the communication: Health, Intellectual Property
    Communication date: 2020-01-09
    Posted date: 2020-02-14
    Communication number: 371-464429 View associated registration

  6. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Stephen Lucas, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-12-12
    Posted date: 2020-01-08
    Communication number: 371-462243 View associated registration

  7. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marilyn Gladu, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2019-12-12
    Posted date: 2020-01-08
    Communication number: 371-462242 View associated registration

  8. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Pierre Poilievre, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-11-28
    Posted date: 2020-01-08
    Communication number: 371-462239 View associated registration

  9. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2019-09-06
    Posted date: 2019-10-09
    Communication number: 371-459961 View associated registration

  10. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Arif Virani, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2019-08-27
    Posted date: 2019-09-23
    Communication number: 371-459845 View associated registration

  11. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marcel Saulnier, Associate ADM | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2019-08-15
    Posted date: 2019-09-12
    Communication number: 371-459435 View associated registration

  12. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Caroline Séguin, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology, Small Business
    Communication date: 2019-07-30
    Posted date: 2019-07-31
    Communication number: 371-458028 View associated registration

  13. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Dominic Cormier, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Internal Trade, Science and Technology
    Communication date: 2019-07-23
    Posted date: 2019-07-31
    Communication number: 371-458018 View associated registration

  14. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Pierre Sabourin, Assistant Deputy Minister | Health Canada (HC)
    • Stefania Trombetti, Acting Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, International Trade
    Communication date: 2019-07-17
    Posted date: 2019-07-31
    Communication number: 371-458023 (amended from 371-458016) View associated registration

  15. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2019-07-15
    Posted date: 2019-07-31
    Communication number: 371-458022 View associated registration

  16. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Science and Technology
    Communication date: 2019-07-11
    Posted date: 2019-07-31
    Communication number: 371-458020 View associated registration

  17. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, International Relations
    Communication date: 2019-07-05
    Posted date: 2019-07-31
    Communication number: 371-458019 View associated registration

  18. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Mathew Clancy -, Press Secretary, Shadow Cabinet | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2019-06-20
    Posted date: 2019-11-28
    Communication number: 371-460934 (amended from 371-457004) View associated registration

  19. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Benjamin Martin, Member's Assistant | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2019-06-18
    Posted date: 2019-07-11
    Communication number: 371-457006 View associated registration

  20. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-06-18
    Posted date: 2019-07-11
    Communication number: 371-457005 View associated registration

  21. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Benjamin Martin, Member's Assistant | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2019-06-14
    Posted date: 2019-07-11
    Communication number: 371-457007 View associated registration

  22. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Greg Fergus, MP for Hull-Aylmer, Parliamentary Secretary to the President of the Treasury Board and Minister of Digital Government | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2019-05-30
    Posted date: 2019-06-12
    Communication number: 371-454915 View associated registration

  23. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sébastien Beaupré-Huot, Special Assistant, Operations and Stakeholder Relations Coordination | Employment and Social Development Canada (ESDC)
    • Dylan Marando, Director of Policy | Employment and Social Development Canada (ESDC)

    Subject Matter of the communication: Health, Industry, Labour, Science and Technology
    Communication date: 2019-05-29
    Posted date: 2019-06-12
    Communication number: 371-454898 View associated registration

  24. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Julia Van Drie, Special Assistant (Policy) | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology, Small Business
    Communication date: 2019-05-16
    Posted date: 2019-06-12
    Communication number: 371-454899 View associated registration

  25. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Assistant Deputy Minister | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, International Trade
    Communication date: 2019-05-13
    Posted date: 2019-06-12
    Communication number: 371-454895 View associated registration

  26. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Tina Green, Assistant Secretary, Regulatory Affairs | Treasury Board Of Canada Secretariat (TBS)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-05-06
    Posted date: 2019-06-12
    Communication number: 371-454897 View associated registration

  27. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Francesco Sorbara, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-30
    Posted date: 2019-05-14
    Communication number: 371-452076 View associated registration

  28. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Michelle Kovacevic, Assistant Deputy Minister | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-26
    Posted date: 2019-05-14
    Communication number: 371-452071 View associated registration

  29. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2019-04-25
    Posted date: 2019-05-14
    Communication number: 371-452062 View associated registration

  30. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jamie Innes, Chief of Staff | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, International Trade, Science and Technology
    Communication date: 2019-04-17
    Posted date: 2019-05-14
    Communication number: 371-452245 (amended from 371-452225) View associated registration

  31. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Taras Zalusky, Director Policy, Procurement and Parliamentary affairs | Public Services and Procurement Canada (PSPC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-16
    Posted date: 2019-05-14
    Communication number: 371-452055 View associated registration

  32. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-11
    Posted date: 2019-05-14
    Communication number: 371-452050 View associated registration

  33. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kate Proctor, Policy Advisor | Treasury Board Of Canada Secretariat (TBS)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2019-04-08
    Posted date: 2019-05-14
    Communication number: 371-452222 View associated registration

  34. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Assistant Secretary to the Cabinet | Privy Council Office (PCO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-05
    Posted date: 2019-05-14
    Communication number: 371-452043 View associated registration

  35. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-04-04
    Posted date: 2019-05-14
    Communication number: 371-452034 View associated registration

  36. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Robertson, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry, Small Business
    Communication date: 2019-03-26
    Posted date: 2019-04-11
    Communication number: 371-449363 View associated registration

  37. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • Abby Hoffman, Assistant Deputy Minister | Health Canada (HC)
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Paul Thompson, Associate Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2019-03-18
    Posted date: 2019-04-11
    Communication number: 371-449360 View associated registration

  38. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Suzy McDonald, Assistant Deputy Minister, FPRSP | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2019-03-04
    Posted date: 2019-04-11
    Communication number: 371-449358 View associated registration

  39. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2019-02-13
    Posted date: 2019-03-08
    Communication number: 371-446781 View associated registration

  40. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jean-Guy Forgeron, Assistant Secretary, Regulatory Affairs Sector | Treasury Board Of Canada Secretariat (TBS)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-02-05
    Posted date: 2019-03-08
    Communication number: 371-446778 View associated registration

  41. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-02-04
    Posted date: 2019-03-08
    Communication number: 371-446773 View associated registration

  42. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2019-02-01
    Posted date: 2019-03-08
    Communication number: 371-446780 View associated registration

  43. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2019-02-01
    Posted date: 2019-03-08
    Communication number: 371-446776 View associated registration

  44. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rachel Wernick, Senior Assistant Deputy Minister | Employment and Social Development Canada (ESDC)

    Subject Matter of the communication: Education, Employment and Training, Health, Immigration, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2019-01-31
    Posted date: 2019-02-12
    Communication number: 371-444941 View associated registration

  45. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Karina Rolland, Stakeholder Relations Advisor | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2019-01-30
    Posted date: 2019-11-28
    Communication number: 371-460932 (amended from 371-444935) View associated registration

  46. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bill Morneau, Minister of Finance | Finance Canada (FIN)
    • Ben Chin, Chief of Staff | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2019-01-25
    Posted date: 2019-02-12
    Communication number: 371-444933 View associated registration

  47. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-01-24
    Posted date: 2019-02-12
    Communication number: 371-444929 View associated registration

  48. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Mathieu Bouchard, Senior Advisor | Prime Minister's Office (PMO)
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)
    • Dominic Cormier, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2019-01-23
    Posted date: 2019-02-12
    Communication number: 371-445038 View associated registration

  49. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ben Chin, Chief of Staff | Finance Canada (FIN)
    • Dev Saxena, Senior Policy Advisor | Finance Canada (FIN)

    Subject Matter of the communication: Consumer Issues, Health, Industry, Intellectual Property
    Communication date: 2019-01-21
    Posted date: 2019-02-12
    Communication number: 371-444926 View associated registration

  50. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Dominic Cormier, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, International Relations
    Communication date: 2019-01-21
    Posted date: 2019-02-12
    Communication number: 371-444924 View associated registration

  51. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2019-01-18
    Posted date: 2019-02-12
    Communication number: 371-444923 View associated registration

  52. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2019-01-18
    Posted date: 2019-02-12
    Communication number: 371-444921 View associated registration

  53. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2019-01-17
    Posted date: 2019-02-12
    Communication number: 371-444919 View associated registration

  54. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2019-01-15
    Posted date: 2019-02-12
    Communication number: 371-444917 View associated registration

  55. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marian Campbell Jarvis, Assistant Secretary to the Cabinet | Privy Council Office (PCO)

    Subject Matter of the communication: Consumer Issues, Health, Industry, Intellectual Property
    Communication date: 2019-01-14
    Posted date: 2019-02-12
    Communication number: 371-444912 View associated registration

  56. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-12-19
    Posted date: 2019-01-11
    Communication number: 371-443329 View associated registration

  57. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • John O'neill, Minister and Deputy Permanent Representative to the World Trade Organisation | Global Affairs Canada (GAC)

    Subject Matter of the communication: Industry, International Trade
    Communication date: 2018-12-05
    Posted date: 2019-01-11
    Communication number: 371-443330 View associated registration

  58. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-11-23
    Posted date: 2018-12-12
    Communication number: 371-441511 View associated registration

  59. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-11-23
    Posted date: 2018-12-12
    Communication number: 371-441509 View associated registration

  60. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Majid Jowhari, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2018-11-08
    Posted date: 2018-12-12
    Communication number: 371-441508 View associated registration

  61. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Mona Fortier, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, International Trade
    Communication date: 2018-11-05
    Posted date: 2018-12-12
    Communication number: 371-441506 View associated registration

  62. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Colin Carrie, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2018-11-05
    Posted date: 2018-12-12
    Communication number: 371-441504 View associated registration

  63. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Frank Baylis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-10-18
    Posted date: 2018-11-14
    Communication number: 371-438523 View associated registration

  64. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2018-10-17
    Posted date: 2018-11-14
    Communication number: 371-438540 View associated registration

  65. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2018-10-17
    Posted date: 2018-11-14
    Communication number: 371-438529 View associated registration

  66. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marilyn Gladu, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2018-10-15
    Posted date: 2018-11-14
    Communication number: 371-438526 View associated registration

  67. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Karina Rolland, Stakeholder Relations Advisor | House of Commons
    • Benjamin Martin, Member's Assistant | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2018-10-11
    Posted date: 2019-11-28
    Communication number: 371-460930 (amended from 371-438516) View associated registration

  68. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • Abby Hoffman, Assistant Deputy Minister - Strategic Policy | Health Canada (HC)
    • Kathryn Nowers, Director of Policy | Health Canada (HC)
    • John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Paul Halucha, Sr Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2018-10-05
    Posted date: 2018-11-14
    Communication number: 371-438500 View associated registration

  69. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2018-10-04
    Posted date: 2018-11-14
    Communication number: 371-438556 View associated registration

  70. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2018-10-03
    Posted date: 2018-11-14
    Communication number: 371-438554 View associated registration

  71. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-10-02
    Posted date: 2018-11-14
    Communication number: 371-438546 View associated registration

  72. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Regional Development, Science and Technology
    Communication date: 2018-09-28
    Posted date: 2018-10-12
    Communication number: 371-435090 View associated registration

  73. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-09-27
    Posted date: 2018-10-12
    Communication number: 371-435096 View associated registration

  74. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Raj Saini, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Internal Trade, Science and Technology
    Communication date: 2018-09-27
    Posted date: 2018-10-12
    Communication number: 371-435091 View associated registration

  75. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Government Procurement, Health, Industry, Science and Technology
    Communication date: 2018-09-26
    Posted date: 2018-10-12
    Communication number: 371-435105 View associated registration

  76. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-09-26
    Posted date: 2018-10-12
    Communication number: 371-435089 View associated registration

  77. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Government Procurement, Health, Industry, Science and Technology
    Communication date: 2018-09-25
    Posted date: 2018-10-12
    Communication number: 371-435107 View associated registration

  78. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Government Procurement, Health, Industry, Science and Technology
    Communication date: 2018-09-21
    Posted date: 2018-10-12
    Communication number: 371-435100 View associated registration

  79. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Karina Rolland-Sardana, Stakeholder Relations Advisor | House of Commons

    Subject Matter of the communication: Health, Industry, Regional Development
    Communication date: 2018-09-18
    Posted date: 2019-11-28
    Communication number: 371-460931 (amended from 371-435094) View associated registration

  80. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Government Procurement, Health, Industry, Science and Technology
    Communication date: 2018-09-18
    Posted date: 2018-10-12
    Communication number: 371-435114 View associated registration

  81. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Government Procurement, Health, Industry, Science and Technology
    Communication date: 2018-09-13
    Posted date: 2018-10-12
    Communication number: 371-435109 View associated registration

  82. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Government Procurement, Health, Industry, Science and Technology
    Communication date: 2018-09-12
    Posted date: 2018-10-12
    Communication number: 371-435113 View associated registration

  83. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Government Procurement, Health, Industry, Science and Technology
    Communication date: 2018-09-12
    Posted date: 2018-10-12
    Communication number: 371-435110 View associated registration

  84. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-09-10
    Posted date: 2018-10-12
    Communication number: 371-435088 View associated registration

  85. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-08-30
    Posted date: 2018-09-10
    Communication number: 371-433279 View associated registration

  86. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Government Procurement, Health, Industry
    Communication date: 2018-08-24
    Posted date: 2018-09-10
    Communication number: 371-433282 View associated registration

  87. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Employment and Training, Government Procurement, Health, Industry, Infrastructure, Intellectual Property, Science and Technology, Small Business
    Communication date: 2018-08-16
    Posted date: 2018-09-10
    Communication number: 371-433283 View associated registration

  88. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-08-14
    Posted date: 2018-09-10
    Communication number: 371-433280 View associated registration

  89. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-08-10
    Posted date: 2018-10-03
    Communication number: 371-434384 View associated registration

  90. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jean-Guy Forgeron, Assistant Secretary, Regulatory Affairs Sector | Treasury Board Of Canada Secretariat (TBS)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-07-26
    Posted date: 2018-08-03
    Communication number: 371-431833 View associated registration

  91. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Chief Statistician of Canada | Statistics Canada (StatCan)
    • Jane Badets, Assistant Chief Statistician | Statistics Canada (StatCan)
    • André Loranger, Assistant Chief Statistician | Statistics Canada (StatCan)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2018-07-23
    Posted date: 2018-08-03
    Communication number: 371-431825 View associated registration

  92. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marian Campbell Jarvis, Assistant Secretary to the Cabinet, Social Development Policy | Privy Council Office (PCO)
    • Kate Power, Policy Advisor | Privy Council Office (PCO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-07-20
    Posted date: 2018-08-03
    Communication number: 371-431829 View associated registration

  93. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-07-19
    Posted date: 2018-08-03
    Communication number: 371-431832 View associated registration

  94. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maximilien Roy, Policy Advisor | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-07-18
    Posted date: 2018-08-03
    Communication number: 371-431831 View associated registration

  95. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-07-17
    Posted date: 2018-08-03
    Communication number: 371-431827 View associated registration

  96. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-07-13
    Posted date: 2018-08-03
    Communication number: 371-431835 View associated registration

  97. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Mathieu Bouchard, Senior Advisor | Prime Minister's Office (PMO)
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, International Relations, Science and Technology
    Communication date: 2018-07-12
    Posted date: 2018-08-03
    Communication number: 371-431828 View associated registration

  98. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-07-04
    Posted date: 2018-08-03
    Communication number: 371-431826 View associated registration

  99. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-06-29
    Posted date: 2018-07-13
    Communication number: 371-430896 View associated registration

  100. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Monique Lugli, Senior Advisor | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-06-28
    Posted date: 2018-07-13
    Communication number: 371-430835 View associated registration

  101. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ginette Petitpas Taylor, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-06-28
    Posted date: 2018-07-13
    Communication number: 371-430833 View associated registration

  102. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-06-28
    Posted date: 2018-07-13
    Communication number: 371-430829 View associated registration

  103. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-06-27
    Posted date: 2018-07-13
    Communication number: 371-430855 View associated registration

  104. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-06-26
    Posted date: 2018-07-13
    Communication number: 371-430895 View associated registration

  105. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-06-22
    Posted date: 2018-07-13
    Communication number: 371-430858 View associated registration

  106. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-06-20
    Posted date: 2018-07-13
    Communication number: 371-430861 View associated registration

  107. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-06-19
    Posted date: 2018-07-13
    Communication number: 371-430878 View associated registration

  108. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-06-19
    Posted date: 2018-07-13
    Communication number: 371-430867 View associated registration

  109. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-06-18
    Posted date: 2018-07-13
    Communication number: 371-430870 View associated registration

  110. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-06-14
    Posted date: 2018-07-13
    Communication number: 371-430884 View associated registration

  111. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-06-14
    Posted date: 2018-07-13
    Communication number: 371-430880 View associated registration

  112. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-06-01
    Posted date: 2018-07-13
    Communication number: 371-430872 View associated registration

  113. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ginette Petitpas Taylor, Minister of Health | Health Canada (HC)
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-06-01
    Posted date: 2018-07-13
    Communication number: 371-430847 View associated registration

  114. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-05-31
    Posted date: 2018-06-12
    Communication number: 371-428027 View associated registration

  115. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-05-30
    Posted date: 2018-06-12
    Communication number: 371-428030 View associated registration

  116. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-05-30
    Posted date: 2018-06-12
    Communication number: 371-428028 View associated registration

  117. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-05-28
    Posted date: 2018-06-12
    Communication number: 371-428021 View associated registration

  118. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-05-25
    Posted date: 2018-06-12
    Communication number: 371-428023 View associated registration

  119. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-05-22
    Posted date: 2018-06-12
    Communication number: 371-428026 View associated registration

  120. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-05-22
    Posted date: 2018-06-12
    Communication number: 371-428025 View associated registration

  121. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-05-17
    Posted date: 2018-06-12
    Communication number: 371-428047 View associated registration

  122. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maximilien Roy, Policy Advisor | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-05-17
    Posted date: 2018-06-12
    Communication number: 371-428046 View associated registration

  123. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maximilien Roy, Policy Advisor | Finance Canada (FIN)

    Subject Matter of the communication: Health
    Communication date: 2018-05-15
    Posted date: 2018-06-12
    Communication number: 371-428045 View associated registration

  124. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-05-15
    Posted date: 2018-06-12
    Communication number: 371-428042 View associated registration

  125. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2018-05-14
    Posted date: 2018-06-12
    Communication number: 371-428041 View associated registration

  126. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-05-11
    Posted date: 2018-06-12
    Communication number: 371-428034 View associated registration

  127. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-05-08
    Posted date: 2018-06-12
    Communication number: 371-428037 View associated registration

  128. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hon Ginette Petitpas Taylor, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-05-05
    Posted date: 2018-06-12
    Communication number: 371-428017 View associated registration

  129. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-05-03
    Posted date: 2018-06-12
    Communication number: 371-428036 View associated registration

  130. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-05-01
    Posted date: 2018-06-12
    Communication number: 371-428032 View associated registration

  131. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)
    • Rick Theis, Policy Advisor | Prime Minister's Office (PMO)
    • Mathieu Bouchard, Senior Advisor | Prime Minister's Office (PMO)
    • Elder Marques, Senior Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2018-04-26
    Posted date: 2018-05-11
    Communication number: 371-425728 View associated registration

  132. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gianluca Cairo, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
    • Hilary Travis, Special Assistant (Policy) | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health
    Communication date: 2018-04-26
    Posted date: 2018-05-11
    Communication number: 371-425725 View associated registration

  133. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Genevieve Hinse, Chief of Staff | Health Canada (HC)
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-04-26
    Posted date: 2018-05-11
    Communication number: 371-425723 View associated registration

  134. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-04-26
    Posted date: 2018-05-11
    Communication number: 371-425721 View associated registration

  135. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-04-17
    Posted date: 2018-05-11
    Communication number: 371-425748 View associated registration

  136. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-04-17
    Posted date: 2018-05-11
    Communication number: 371-425733 View associated registration

  137. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2018-04-06
    Posted date: 2018-05-11
    Communication number: 371-425749 View associated registration

  138. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-04-06
    Posted date: 2018-05-11
    Communication number: 371-425743 View associated registration

  139. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-04-05
    Posted date: 2018-05-11
    Communication number: 371-425745 View associated registration

  140. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maximilien Roy, Policy Advisor | Finance Canada (FIN)

    Subject Matter of the communication: Health
    Communication date: 2018-04-04
    Posted date: 2018-05-11
    Communication number: 371-425741 View associated registration

  141. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2018-04-04
    Posted date: 2018-05-11
    Communication number: 371-425735 View associated registration

  142. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Abby Hoffman, Assistant Deputy Minister - Strategic Policy | Health Canada (HC)
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Gianluca Cairo, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
    • Genevieve Hinse, Chief of Staff | Health Canada (HC)
    • Kathryn Nowers, Director of Policy | Health Canada (HC)
    • Hilary Travis, Special Assistant (Policy) | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2018-04-03
    Posted date: 2018-05-14
    Communication number: 371-426048 View associated registration

  143. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Travis, Special Assistant (Policy) | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-30
    Posted date: 2018-04-13
    Communication number: 371-423836 View associated registration

  144. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maximilien Roy, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Science and Technology, Taxation and Finance
    Communication date: 2018-03-29
    Posted date: 2018-04-13
    Communication number: 371-423820 View associated registration

  145. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Richard Botham, Assistant Deputy Minister | Finance Canada (FIN)

    Subject Matter of the communication: Health, Science and Technology, Taxation and Finance
    Communication date: 2018-03-29
    Posted date: 2018-04-13
    Communication number: 371-423778 View associated registration

  146. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-27
    Posted date: 2018-04-13
    Communication number: 371-423795 View associated registration

  147. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-20
    Posted date: 2018-04-13
    Communication number: 371-423808 View associated registration

  148. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-14
    Posted date: 2018-04-13
    Communication number: 371-423815 View associated registration

  149. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-14
    Posted date: 2018-04-13
    Communication number: 371-423799 View associated registration

  150. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-13
    Posted date: 2018-04-13
    Communication number: 371-423806 View associated registration

  151. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-12
    Posted date: 2018-04-13
    Communication number: 371-423817 View associated registration

  152. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-12
    Posted date: 2018-04-13
    Communication number: 371-423803 View associated registration

  153. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-08
    Posted date: 2018-04-13
    Communication number: 371-423810 View associated registration

  154. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-08
    Posted date: 2018-04-13
    Communication number: 371-423801 View associated registration

  155. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Christopher MacLennan, Assistant Deputy Minister | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, International Relations
    Communication date: 2018-03-07
    Posted date: 2018-04-13
    Communication number: 371-423770 View associated registration

  156. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jonathan Fried, Coordinator, International Economic Relations | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, International Relations
    Communication date: 2018-03-07
    Posted date: 2018-04-13
    Communication number: 371-423767 View associated registration

  157. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jean-Guy Forgeron, Assistant Secretary, Regulatory Affairs Secretariat | Treasury Board Of Canada Secretariat (TBS)

    Subject Matter of the communication: Health, Industry
    Communication date: 2018-03-02
    Posted date: 2018-04-13
    Communication number: 371-423774 View associated registration

  158. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • John Burnett, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-02-20
    Posted date: 2018-03-13
    Communication number: 371-421450 View associated registration

  159. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health
    Communication date: 2018-02-13
    Posted date: 2018-03-13
    Communication number: 371-421446 View associated registration

  160. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Emmanuella Lambropoulos, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-02-07
    Posted date: 2018-03-13
    Communication number: 371-421445 View associated registration

  161. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Mona Nemer, Chief of Science Advisor | Innovation, Science and Economic Development Canada (ISED)
    • Luc Gauthier, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2018-02-05
    Posted date: 2018-03-13
    Communication number: 371-421449 View associated registration

  162. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gianluca Cairo, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-02-05
    Posted date: 2018-03-13
    Communication number: 371-421447 View associated registration

  163. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hon Navdeep Bains, Minister | Innovation, Science and Economic Development Canada (ISED)
    • Gianluca Cairo, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)
    • Susan Bincoletto, Ambassador of Canada to Switzerland and Liechtenstein | Global Affairs Canada (GAC)

    Subject Matter of the communication: Industry, Intellectual Property, International Trade
    Communication date: 2018-01-23
    Posted date: 2018-02-09
    Communication number: 371-419144 View associated registration

  164. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
    • Hilary Travis, Special Assistant (Policy) | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2017-11-14
    Posted date: 2017-12-13
    Communication number: 371-415681 View associated registration

  165. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • Abby Hoffman, Assistant Deputy Minister - Strategic Policy | Health Canada (HC)
    • Pierre Sabourin, Assistant Deputy Minister | Health Canada (HC)
    • Kendal Weber, Associate Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2017-11-14
    Posted date: 2017-12-13
    Communication number: 371-415675 View associated registration

  166. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Don Davies, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2017-11-08
    Posted date: 2017-12-13
    Communication number: 371-415679 View associated registration

  167. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Karen Ludwig, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-11-02
    Posted date: 2017-12-13
    Communication number: 371-415678 View associated registration

  168. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Tracey Ramsey, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-11-02
    Posted date: 2017-12-13
    Communication number: 371-415676 View associated registration

  169. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2017-10-30
    Posted date: 2017-11-21
    Communication number: 371-414058 (amended from 371-413065) View associated registration

  170. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Earl Dreeshen, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-10-30
    Posted date: 2017-11-15
    Communication number: 371-413069 View associated registration

  171. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David McGovern, Associate Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2017-08-30
    Posted date: 2017-09-11
    Communication number: 371-407527 (amended from 371-407520) View associated registration

  172. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Abby Hoffman, Assistant Deputy Minister - Strategic Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2017-07-11
    Posted date: 2017-08-15
    Communication number: 371-406506 View associated registration

  173. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
    • Parvinder Sachdeva, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2017-07-06
    Posted date: 2017-08-15
    Communication number: 371-406504 View associated registration

  174. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Genevieve Hinse, Chief of Staff | Health Canada (HC)
    • Caroline Pitfield, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2017-06-29
    Posted date: 2017-07-07
    Communication number: 371-404689 View associated registration

  175. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Megan Buttle, Special Assistant | Innovation, Science and Economic Development Canada (ISED)
    • Javid Dharas, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • Parvidner Sachdeva, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-04-13
    Posted date: 2017-05-15
    Communication number: 371-400524 View associated registration

  176. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David MacNaughton, Canada's Ambassador to the United States | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-04-11
    Posted date: 2017-05-15
    Communication number: 371-400529 (amended from 371-400523) View associated registration

  177. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Francois-Philippe Champagne, Minister of International Trade | Global Affairs Canada (GAC)

    Subject Matter of the communication: Industry, Intellectual Property, International Trade
    Communication date: 2017-04-10
    Posted date: 2017-05-15
    Communication number: 371-400526 View associated registration

  178. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Pierre Sabourin, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, International Trade
    Communication date: 2017-04-05
    Posted date: 2017-05-15
    Communication number: 371-400525 View associated registration

  179. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Daniel Costello, Ambassador of Canada to the European Union | Global Affairs Canada (GAC)

    Subject Matter of the communication: Industry, Intellectual Property, International Trade
    Communication date: 2017-04-04
    Posted date: 2017-05-15
    Communication number: 371-400528 View associated registration

  180. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Darshan Kang, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-04-03
    Posted date: 2017-05-15
    Communication number: 371-400527 View associated registration

  181. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Tyler Meredith, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-03-15
    Posted date: 2017-04-15
    Communication number: 371-398406 View associated registration

  182. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David Lametti, Member of Parliament | House of Commons
    • Parvinder Sachdeva, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-02-23
    Posted date: 2017-03-15
    Communication number: 371-396082 View associated registration

  183. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Frank Baylis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-02-07
    Posted date: 2017-03-15
    Communication number: 371-396092 View associated registration

  184. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-02-03
    Posted date: 2017-03-15
    Communication number: 371-396088 View associated registration

  185. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada European-Union) | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2017-01-30
    Posted date: 2017-02-15
    Communication number: 371-393333 View associated registration

  186. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Megan Buttle, Member's Assistant | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-12-07
    Posted date: 2017-01-16
    Communication number: 371-392179 View associated registration

  187. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David Lametti, Member of Parliament | House of Commons
    • Megan Buttle, Member's Assistant | House of Commons
    • Vincent Garneau, Director of Parliamentary Affairs | Global Affairs Canada (GAC)
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-12-01
    Posted date: 2017-01-16
    Communication number: 371-392178 View associated registration

  188. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Parvinder Sachdeva, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • Javid Dharas, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • Marc Gervais, Director of Parliamentary Affairs and Issues Management | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-12-01
    Posted date: 2017-01-16
    Communication number: 371-392176 View associated registration

  189. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Honourable Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-11-16
    Posted date: 2016-12-15
    Communication number: 371-389245 View associated registration

  190. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Javid Dharas, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-11-16
    Posted date: 2016-12-15
    Communication number: 371-389244 View associated registration

  191. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Dev Saxena, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • Javid Dharas, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-11-04
    Posted date: 2016-12-15
    Communication number: 371-389246 View associated registration

  192. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Javid Dharas, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-11-04
    Posted date: 2016-12-15
    Communication number: 371-389243 View associated registration

  193. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Dev Saxena, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2016-10-20
    Posted date: 2016-11-15
    Communication number: 371-386814 View associated registration

  194. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Policy Advisor | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-10-07
    Posted date: 2016-11-15
    Communication number: 371-386816 View associated registration

  195. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Stephanie Delorme, Stakeholder Relations Advisor | House of Commons
    • Cam Vidler, Senior Economic Policy Advisor | House of Commons
    • Katie Locke, Manager Stakeholder Relations / Sr. Advisor | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-08-22
    Posted date: 2019-11-28
    Communication number: 371-460933 (amended from 371-383127) View associated registration

  196. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Abby Hoffman, Assistant Deputy Minister | Health Canada (HC)
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-07-28
    Posted date: 2016-08-15
    Communication number: 371-381927 View associated registration

  197. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Christopher A. Berzins, Director of Policy | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-07-27
    Posted date: 2016-08-15
    Communication number: 371-381929 View associated registration

  198. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Associate Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-07-26
    Posted date: 2016-08-15
    Communication number: 371-381928 View associated registration

  199. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Claude-Éric Gagné, Deputy Director of Operations | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-06-16
    Posted date: 2016-07-15
    Communication number: 371-381003 View associated registration

  200. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Associate Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-06-14
    Posted date: 2016-07-15
    Communication number: 371-381001 View associated registration

  201. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Majid Jowhari, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-06-06
    Posted date: 2016-07-15
    Communication number: 371-381000 View associated registration

  202. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steven MacKinnon, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-06-02
    Posted date: 2016-07-15
    Communication number: 371-380999 View associated registration

  203. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Carlene Variyan, Director of Parliamentary Affairs | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-06-02
    Posted date: 2016-07-15
    Communication number: 371-380998 View associated registration

  204. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Celina Caesar-Chavannes, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-06-02
    Posted date: 2016-07-15
    Communication number: 371-380996 View associated registration

  205. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Don Davies, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-06-01
    Posted date: 2016-07-15
    Communication number: 371-380995 View associated registration

  206. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Associate Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-05-24
    Posted date: 2016-06-15
    Communication number: 371-378095 View associated registration

  207. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Cyrus Reporter, Senior Advisor to the Prime Minister | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-05-16
    Posted date: 2018-09-10
    Communication number: 371-433285 (amended from 371-378089) View associated registration

  208. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • Lawrence Cheung, Senior Policy Advisor | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-05-13
    Posted date: 2016-06-15
    Communication number: 371-378093 View associated registration

  209. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Les Linklater, Deputy Secretariat to the Cabinet | Privy Council Office (PCO)
    • Ian Burney, Assistant Secretary to the Cabinet | Privy Council Office (PCO)

    Subject Matter of the communication: Health, Intellectual Property, International Trade
    Communication date: 2016-05-13
    Posted date: 2016-06-15
    Communication number: 371-378090 View associated registration

  210. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Robert Oliphant, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-05-12
    Posted date: 2016-06-15
    Communication number: 371-378094 View associated registration

  211. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rachael Harder, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Intellectual Property, Science and Technology
    Communication date: 2016-05-11
    Posted date: 2016-06-15
    Communication number: 371-378096 View associated registration

  212. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Philip Jennings, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-05-10
    Posted date: 2016-06-15
    Communication number: 371-378087 View associated registration

  213. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Vincent Garneau, Director of Parliamentary Affairs | Global Affairs Canada (GAC)
    • Christopher Berzins, Director of Policy | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-05-06
    Posted date: 2016-06-15
    Communication number: 371-378092 View associated registration

  214. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hilary Geller, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Justice and Law Enforcement, Science and Technology
    Communication date: 2016-05-04
    Posted date: 2016-06-15
    Communication number: 371-378091 View associated registration

  215. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Raj Grewal, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-05-02
    Posted date: 2016-06-15
    Communication number: 371-378088 View associated registration

  216. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Dan Costello, Assistant Deputy Minister, Europe | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-04-26
    Posted date: 2016-05-16
    Communication number: 371-375859 View associated registration

  217. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Associate Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-04-20
    Posted date: 2016-05-16
    Communication number: 371-375861 View associated registration

  218. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Terry Beech, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-04-11
    Posted date: 2016-05-16
    Communication number: 371-375862 View associated registration

  219. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Justin To, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-04-05
    Posted date: 2016-05-16
    Communication number: 371-375860 View associated registration

  220. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sarah Hussaini, Policy Advisor | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-31
    Posted date: 2016-04-15
    Communication number: 371-373799 View associated registration

  221. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Francesco Sorbara, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-31
    Posted date: 2016-04-15
    Communication number: 371-373798 View associated registration

  222. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Tracey Ramsey, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-25
    Posted date: 2016-04-15
    Communication number: 371-373797 View associated registration

  223. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jonathan T. Fried, Ambassador and Permanent Representative of Canada to the WTO, Geneva | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-22
    Posted date: 2016-04-15
    Communication number: 371-373796 View associated registration

  224. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marc Serré, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-22
    Posted date: 2016-04-15
    Communication number: 371-373795 View associated registration

  225. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Terry Beech, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-21
    Posted date: 2016-04-15
    Communication number: 371-373794 View associated registration

  226. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Scott Simms, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-21
    Posted date: 2016-04-15
    Communication number: 371-373793 View associated registration

  227. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-16
    Posted date: 2016-04-15
    Communication number: 371-373792 View associated registration

  228. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Cam Vidler, Senior Economic Policy Advisor | House of Commons
    • Katie Locke, Manager, Stakeholder Relations / Senior Advisor | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-10
    Posted date: 2016-04-15
    Communication number: 371-373791 View associated registration

  229. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Chrystia Freeland, Minister | Global Affairs Canada (GAC)
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-03
    Posted date: 2016-04-15
    Communication number: 371-373790 View associated registration

  230. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Elder Marques, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-03-02
    Posted date: 2016-04-15
    Communication number: 371-373789 View associated registration

  231. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marco Mendicino, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-25
    Posted date: 2016-03-15
    Communication number: 371-371050 View associated registration

  232. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Colin Fraser, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-25
    Posted date: 2016-03-15
    Communication number: 371-371048 View associated registration

  233. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Barbara Glover, Assistant Deputy Minister | Public Services and Procurement Canada (PSPC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-25
    Posted date: 2016-03-15
    Communication number: 371-371043 View associated registration

  234. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Pablo Rodriguez, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-23
    Posted date: 2016-03-15
    Communication number: 371-371047 View associated registration

  235. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David Lametti, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-18
    Posted date: 2016-03-15
    Communication number: 371-371045 View associated registration

  236. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Colin Bird, Minister-Counselor | Global Affairs Canada (GAC)
    • Gilles Gauthier, Minister | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-17
    Posted date: 2016-03-15
    Communication number: 371-372337 View associated registration

  237. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jane Philpott, Minister | Health Canada (HC)
    • Caroline Pitfield, Director of Policy | Health Canada (HC)
    • Genevieve Hinse, Chief of Staff | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-08
    Posted date: 2016-03-15
    Communication number: 371-371052 View associated registration

  238. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alexandra Bugailskis, Assistant Deputy Minister, Europe, Middle East and Maghreb | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-04
    Posted date: 2016-03-15
    Communication number: 371-371058 View associated registration

  239. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-04
    Posted date: 2016-03-15
    Communication number: 371-371056 View associated registration

  240. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Francis Drouin, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-02-01
    Posted date: 2016-03-15
    Communication number: 371-371049 View associated registration

  241. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • TJ Harvey, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-28
    Posted date: 2016-02-15
    Communication number: 371-368514 View associated registration

  242. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ginette Petitpas Taylor, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-27
    Posted date: 2016-02-15
    Communication number: 371-368516 View associated registration

  243. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rodger Cuzner, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-27
    Posted date: 2016-02-15
    Communication number: 371-368507 View associated registration

  244. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rob Rosenfeld, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-26
    Posted date: 2016-02-15
    Communication number: 371-368504 View associated registration

  245. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-25
    Posted date: 2016-02-15
    Communication number: 371-368445 View associated registration

  246. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sean Fraser, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-21
    Posted date: 2016-02-15
    Communication number: 371-368511 View associated registration

  247. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Robert Asselin, Director of Policy | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-21
    Posted date: 2016-02-15
    Communication number: 371-368509 View associated registration

  248. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Greg Fergus, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-21
    Posted date: 2016-02-15
    Communication number: 371-368502 View associated registration

  249. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Tyler Meredith, Policy Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2016-01-18
    Posted date: 2016-02-15
    Communication number: 371-368517 View associated registration

  250. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • William Blair, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-12-10
    Posted date: 2016-01-15
    Communication number: 371-366336 View associated registration

  251. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K Ogilvie, Honourable Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-12-09
    Posted date: 2016-01-15
    Communication number: 371-366333 View associated registration

  252. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sven Spengemann, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-12-08
    Posted date: 2016-01-15
    Communication number: 371-366332 View associated registration

  253. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jennifer O'Connell, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-12-08
    Posted date: 2016-01-15
    Communication number: 371-366331 View associated registration

  254. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • John Pecman, Commissioner of Competition | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-12-07
    Posted date: 2016-01-15
    Communication number: 371-366334 View associated registration

  255. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-12-01
    Posted date: 2016-01-15
    Communication number: 371-366335 View associated registration

  256. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Randall Garrison, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-11-30
    Posted date: 2015-12-15
    Communication number: 371-364713 View associated registration

  257. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gavin Liddy, Associate Deputy Minister | Public Services and Procurement Canada (PSPC)
    • Barbara Glover, Assistant Deputy Minister | Public Services and Procurement Canada (PSPC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-11-27
    Posted date: 2015-12-15
    Communication number: 371-364711 View associated registration

  258. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Danielle Lauzon, Telecommunications Project Officer | Shared Services Canada (SSC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-11-26
    Posted date: 2015-12-15
    Communication number: 371-364712 View associated registration

  259. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Dan Costello, Assistant Deputy Minister, Europe | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-11-24
    Posted date: 2015-12-15
    Communication number: 371-364742 View associated registration

  260. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Johanne Belisle, Commissioner of Patents, Registrar of Trade-marks and CEO | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-11-10
    Posted date: 2015-12-15
    Communication number: 371-364710 View associated registration

  261. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Associate Assistant Deputy Minister | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-10-26
    Posted date: 2015-11-16
    Communication number: 371-363347 View associated registration

  262. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Susan Gregson, Assistant Deputy Minister | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-10-23
    Posted date: 2015-11-16
    Communication number: 371-363346 View associated registration

  263. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-10-23
    Posted date: 2015-11-16
    Communication number: 371-363345 View associated registration

  264. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-10-13
    Posted date: 2015-11-16
    Communication number: 371-363344 View associated registration

  265. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2015-09-18
    Posted date: 2015-10-15
    Communication number: 371-362164 View associated registration

  266. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Associate Deputy Minister | Health Canada (HC)
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2015-09-16
    Posted date: 2015-10-15
    Communication number: 371-362162 View associated registration

  267. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health
    Communication date: 2015-09-11
    Posted date: 2015-10-15
    Communication number: 371-362163 View associated registration

  268. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Honourable Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-08-27
    Posted date: 2015-09-15
    Communication number: 371-360865 View associated registration

  269. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Associate Assistant Deputy Minister | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-07-28
    Posted date: 2015-08-15
    Communication number: 371-359502 View associated registration

  270. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jonathan T. Fried, Ambassador and Permanent Representative of Canada | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-06-24
    Posted date: 2015-07-15
    Communication number: 371-357605 View associated registration

  271. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David Van Hemmen, Director of Budget Planning | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-06-23
    Posted date: 2015-07-15
    Communication number: 371-357608 View associated registration

  272. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alexandra MacEachern, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-06-11
    Posted date: 2015-07-15
    Communication number: 371-357609 View associated registration

  273. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Lise-Ann Jackson, Deputy Chief of Staff/Director, Strategic Planning & Stakeholder Relations | Foreign Affairs, Trade and Development Canada
    • Kirsten Hillman, Associate Assistant Deputy Minister | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-06-11
    Posted date: 2015-07-15
    Communication number: 371-357606 View associated registration

  274. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-06-04
    Posted date: 2015-07-15
    Communication number: 371-357604 View associated registration

  275. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-06-03
    Posted date: 2015-07-15
    Communication number: 371-357603 View associated registration

  276. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-05-29
    Posted date: 2015-06-15
    Communication number: 371-355820 View associated registration

  277. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Associate Assistant Deputy Minister | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-05-12
    Posted date: 2015-06-15
    Communication number: 371-355821 View associated registration

  278. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-05-06
    Posted date: 2015-06-15
    Communication number: 371-355822 View associated registration

  279. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hedy Fry, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-22
    Posted date: 2015-05-15
    Communication number: 371-353452 View associated registration

  280. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Associate Assistant Deputy Minister | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-17
    Posted date: 2015-05-15
    Communication number: 371-353482 View associated registration

  281. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Trina Morissette, Director of Policy and Stakeholder Relations | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2015-04-17
    Posted date: 2015-05-15
    Communication number: 371-353454 View associated registration

  282. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Halucha, Associate Assistant Deputy Minister | Industry Canada
    • John Knubley, Deputy Minister | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-15
    Posted date: 2015-05-15
    Communication number: 371-353481 View associated registration

  283. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-14
    Posted date: 2015-05-15
    Communication number: 371-353451 View associated registration

  284. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-14
    Posted date: 2015-05-15
    Communication number: 371-353448 View associated registration

  285. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-08
    Posted date: 2015-05-15
    Communication number: 371-353446 View associated registration

  286. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-07
    Posted date: 2015-05-15
    Communication number: 371-353445 View associated registration

  287. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kirsten Hillman, Associate Assistant Deputy Minister | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-02
    Posted date: 2015-05-15
    Communication number: 371-353450 View associated registration

  288. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Phil Harwood, Policy Advisor, Fiscal & Economic Affairs | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-04-01
    Posted date: 2015-05-15
    Communication number: 371-353449 View associated registration

  289. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ed Holder, Minister of State | Industry Canada
    • James S. Cowan, Leader of the Opposition | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-03-31
    Posted date: 2015-04-15
    Communication number: 371-350823 View associated registration

  290. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Susan Gregson, Assistant Deputy Minister | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-03-30
    Posted date: 2015-04-15
    Communication number: 371-350819 View associated registration

  291. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rona Ambrose, Minister of Health | Health Canada (HC)
    • Nik Zylstra, Senior Policy Advisor | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-03-13
    Posted date: 2015-04-15
    Communication number: 371-351029 View associated registration

  292. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kennedy Hong, Manager | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-03-09
    Posted date: 2015-04-15
    Communication number: 371-350814 View associated registration

  293. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • Paul Glover, Associate Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-03-06
    Posted date: 2015-04-15
    Communication number: 371-350818 View associated registration

  294. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Moran, Deputy Chief of Staff | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-03-04
    Posted date: 2015-04-15
    Communication number: 371-350815 View associated registration

  295. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sean Speer, Special Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-02-24
    Posted date: 2015-03-16
    Communication number: 371-348863 View associated registration

  296. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Karl Belanger, Principal Secretary | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-02-18
    Posted date: 2015-03-16
    Communication number: 371-348864 View associated registration

  297. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sean Speer, Special Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-02-18
    Posted date: 2015-03-16
    Communication number: 371-348862 View associated registration

  298. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Candice Baetz, Policy Advisor | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-02-12
    Posted date: 2015-03-16
    Communication number: 371-348860 View associated registration

  299. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sean Speer, Special Advisor | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-02-11
    Posted date: 2015-03-16
    Communication number: 371-348861 View associated registration

  300. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-02-11
    Posted date: 2015-03-16
    Communication number: 371-348859 View associated registration

  301. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alexandra MacEachern, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-02-09
    Posted date: 2015-03-16
    Communication number: 371-348858 View associated registration

  302. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Nik Zylstra, Senior Policy Advisor | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2015-02-02
    Posted date: 2015-03-16
    Communication number: 371-348857 View associated registration

  303. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Peggy Nash, Member of Parliament | House of Commons
    • Dan Harris, Member of Parliament | House of Commons

    Subject Matter of the communication: Financial Institutions, Health, Industry, International Trade
    Communication date: 2015-01-27
    Posted date: 2015-02-16
    Communication number: 371-347126 View associated registration

  304. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Don Davies, Member of Parliament | House of Commons
    • Laurin Liu, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-01-27
    Posted date: 2015-02-16
    Communication number: 371-347125 View associated registration

  305. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Florian Olsen, Policy and Stakeholder Relations Officer | House of Commons
    • Kerry-Ann Taylor, Communications Officer | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-01-27
    Posted date: 2015-02-16
    Communication number: 371-347120 View associated registration

  306. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • François Desmarais, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-01-23
    Posted date: 2015-02-16
    Communication number: 371-347124 View associated registration

  307. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • John Knubley, Deputy Minister | Industry Canada
    • Kelly Gillis, Associate Deputy Minister | Industry Canada
    • Mitch Davies, Assistant Deputy Minister | Industry Canada
    • Philip Jennings, Assistant Deputy Minister | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-01-19
    Posted date: 2015-02-16
    Communication number: 371-347121 View associated registration

  308. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kirsten Hillman, Associate Assistant Deputy Minister | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2015-01-14
    Posted date: 2015-02-16
    Communication number: 371-347123 View associated registration

  309. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kirsty Duncan, Member of Parliament | House of Commons
    • Scott Myres, Special Assistant, Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-12-01
    Posted date: 2015-01-15
    Communication number: 371-343337 View associated registration

  310. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Anil Arora, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Relations
    Communication date: 2014-11-24
    Posted date: 2014-12-15
    Communication number: 371-339612 View associated registration

  311. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • James Maunder, Chief of Staff | Industry Canada

    Subject Matter of the communication: Health, Intellectual Property, International Trade, Science and Technology
    Communication date: 2014-11-04
    Posted date: 2014-12-15
    Communication number: 371-339611 View associated registration

  312. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David Sweet, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-11-04
    Posted date: 2014-12-15
    Communication number: 371-339610 View associated registration

  313. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-11-04
    Posted date: 2014-12-15
    Communication number: 371-339609 View associated registration

  314. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ben Lobb, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-11-04
    Posted date: 2014-12-15
    Communication number: 371-339608 View associated registration

  315. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David Wells, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-30
    Posted date: 2014-11-15
    Communication number: 371-337784 View associated registration

  316. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Randy Hoback, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-30
    Posted date: 2014-11-15
    Communication number: 371-337783 View associated registration

  317. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-23
    Posted date: 2014-11-15
    Communication number: 371-337789 View associated registration

  318. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ben Lobb, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-23
    Posted date: 2014-11-15
    Communication number: 371-337782 View associated registration

  319. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Susan Gregson, Assistant Deputy Minister, Asia Pacific | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: International Relations
    Communication date: 2014-10-09
    Posted date: 2014-11-15
    Communication number: 371-337781 View associated registration

  320. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Don Davies, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-08
    Posted date: 2014-11-15
    Communication number: 371-337780 View associated registration

  321. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Chrystia Freeland, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-06
    Posted date: 2014-11-15
    Communication number: 371-337779 View associated registration

  322. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-03
    Posted date: 2014-11-15
    Communication number: 371-337778 View associated registration

  323. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ashley Andrades, Special Assistant | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-03
    Posted date: 2014-11-15
    Communication number: 371-337777 View associated registration

  324. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David Plunkett, Ambassador of Canada to the European Union | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-10-03
    Posted date: 2014-11-15
    Communication number: 371-337776 (amended from 371-337775) View associated registration

  325. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gordon Brown, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-09-25
    Posted date: 2014-10-15
    Communication number: 371-335405 View associated registration

  326. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • James Munder, Chief of Staff | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2014-09-22
    Posted date: 2014-10-15
    Communication number: 371-335404 View associated registration

  327. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jeremy Hunt, Director, Stakeholder Relations and Outreach | Prime Minister's Office (PMO)
    • Cynthia Tran, Advisor, Stakeholder Relations & Outreach | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2014-09-18
    Posted date: 2014-10-15
    Communication number: 371-335403 View associated registration

  328. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Julie Vaux, Chief of Staff | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-09-16
    Posted date: 2014-10-15
    Communication number: 371-335402 View associated registration

  329. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ken Bednarek, Senior Letigation Advisor | Justice Canada (JC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-09-16
    Posted date: 2014-10-15
    Communication number: 371-335400 View associated registration

  330. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alexandra MacEachern, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-09-15
    Posted date: 2014-10-15
    Communication number: 371-335399 View associated registration

  331. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jess Weiser, Director of Policy | Health Canada (HC)
    • Clarke Olsen, Director of Parliamentary Affairs | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2014-09-03
    Posted date: 2014-10-15
    Communication number: 371-335397 View associated registration

  332. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bradley Lattanzi, Policy Advisor, Science and Technology | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-08-25
    Posted date: 2014-09-15
    Communication number: 371-333270 View associated registration

  333. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2014-08-19
    Posted date: 2014-09-15
    Communication number: 371-333269 View associated registration

  334. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry
    Communication date: 2014-08-19
    Posted date: 2014-09-15
    Communication number: 371-333267 View associated registration

  335. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-07-10
    Posted date: 2014-08-15
    Communication number: 371-331099 View associated registration

  336. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jess Weiser, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-07-10
    Posted date: 2014-08-15
    Communication number: 371-331098 View associated registration

  337. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • David Belous, Manager, Stakeholder Relations & Outreach | Prime Minister's Office (PMO)
    • Meredith Lilly, Policy Advisor, Foreign Affairs & Trade | Prime Minister's Office (PMO)
    • Lise-Ann Jackson, Director of Operations and Special Projects | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-07-09
    Posted date: 2014-08-15
    Communication number: 371-331097 View associated registration

  338. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Mitch Davies, Assistant Deputy Minister | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-07-07
    Posted date: 2014-08-15
    Communication number: 371-331096 View associated registration

  339. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Honourable Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-07-03
    Posted date: 2014-08-15
    Communication number: 371-331095 View associated registration

  340. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jean Rousseau, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-06-28
    Posted date: 2014-07-15
    Communication number: 371-329654 View associated registration

  341. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Mike Lake, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2014-06-24
    Posted date: 2014-07-15
    Communication number: 371-329653 View associated registration

  342. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Julie Vaux, Chief of Staff | Health Canada (HC)
    • Jess Weiser, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2014-06-13
    Posted date: 2014-07-15
    Communication number: 371-329652 View associated registration

  343. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry
    Communication date: 2014-06-12
    Posted date: 2014-07-15
    Communication number: 371-329651 View associated registration

  344. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gordon Venner, Assistant Deputy Minister | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, International Relations
    Communication date: 2014-06-04
    Posted date: 2014-07-15
    Communication number: 371-329650 View associated registration

  345. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bradley Lattanzi, Policy Advisor, Science and Technology | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-06-03
    Posted date: 2014-07-15
    Communication number: 371-329649 View associated registration

  346. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alayna Johnson, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-05-23
    Posted date: 2014-06-15
    Communication number: 371-326578 View associated registration

  347. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jonathan Fried, Ambassador and Permanent Representative of Canada to the WTO, Geneva | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-05-20
    Posted date: 2014-06-15
    Communication number: 371-326577 View associated registration

  348. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-05-09
    Posted date: 2014-06-15
    Communication number: 371-326576 View associated registration

  349. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Diane Jacovella, Assistant Deputy Minister | Foreign Affairs, Trade and Development Canada
    • Paul Samson, A/Assistant Deputy Minister | Foreign Affairs, Trade and Development Canada
    • Matthew Senft, Policy Advisor | Foreign Affairs, Trade and Development Canada
    • Joel Bernard, Policy Advisor for La Francophonie | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-05-08
    Posted date: 2014-06-15
    Communication number: 371-326581 View associated registration

  350. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Lois Brown, Member of Parliament | House of Commons
    • Paul Dewar, Member of Parliament | House of Commons
    • Geoff Regan, Member of Parliament | House of Commons
    • Carolyn Bennett, Member of Parliament | House of Commons
    • Wayne Easter, Member of Parliament | House of Commons
    • Dennis Dawson, Senator | Senate of Canada
    • Terry Mercer, Senator | Senate of Canada
    • JoAnne Buth, Senator | Senate of Canada
    • Matthew Senft, Policy Advisor | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-05-08
    Posted date: 2014-06-15
    Communication number: 371-326573 View associated registration

  351. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Meredith Lilly, Policy Advisor, Foreign Affairs & Trade | Prime Minister's Office (PMO)
    • Cynthia Tran, Advisor, Stakeholder Relations & Outreach | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-05-08
    Posted date: 2014-06-15
    Communication number: 371-326571 View associated registration

  352. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alayna Johnson, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-05-07
    Posted date: 2014-06-15
    Communication number: 371-326570 View associated registration

  353. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Graham Howell, Director of Strategic Planning | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-05-06
    Posted date: 2014-06-15
    Communication number: 371-326569 View associated registration

  354. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alayna Johnson, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-04-29
    Posted date: 2014-05-15
    Communication number: 371-323730 View associated registration

  355. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • James Moore, Minister of Industry | Industry Canada
    • Alayna Johnson, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-04-29
    Posted date: 2014-05-15
    Communication number: 371-323700 View associated registration

  356. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Cynthia Tran, Advisor, Stakeholder Relations & Outreach | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-04-14
    Posted date: 2014-05-15
    Communication number: 371-323699 View associated registration

  357. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Erin O'Toole, Parliamentary Secretary | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-04-07
    Posted date: 2014-05-15
    Communication number: 371-323703 View associated registration

  358. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alayna Johnson, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-04-07
    Posted date: 2014-05-15
    Communication number: 371-323698 View associated registration

  359. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-04-02
    Posted date: 2014-05-15
    Communication number: 371-323702 View associated registration

  360. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Howard Alper, Chair, Science, Technology and Innovation Counsil Secretriat | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-03-14
    Posted date: 2014-04-15
    Communication number: 371-321272 View associated registration

  361. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-03-10
    Posted date: 2014-04-15
    Communication number: 371-321271 View associated registration

  362. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Abby Hoffman, Assistant Deputy Minister - Strategic Policy | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2014-02-20
    Posted date: 2014-03-15
    Communication number: 371-318693 View associated registration

  363. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jonathan Aitchison, Policy Advisor | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-02-19
    Posted date: 2014-03-15
    Communication number: 371-318691 View associated registration

  364. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Julie Vaux, Chief of Staff | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-02-11
    Posted date: 2014-03-15
    Communication number: 371-318690 View associated registration

  365. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Graham Howell, Director of Strategic Planning | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2014-02-07
    Posted date: 2014-03-15
    Communication number: 371-318689 View associated registration

  366. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ben Lobb, Member of Parliament | House of Commons
    • David Wilks, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2014-01-30
    Posted date: 2014-02-15
    Communication number: 371-315452 View associated registration

  367. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rona Ambrose, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2014-01-24
    Posted date: 2014-02-15
    Communication number: 371-315451 View associated registration

  368. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bradley Lattanzi, Policy Advisor, Science and Technology | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2014-01-23
    Posted date: 2014-02-15
    Communication number: 371-315450 View associated registration

  369. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Graham Howell, Director of Strategic Planning | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2014-01-21
    Posted date: 2014-02-15
    Communication number: 371-315449 View associated registration

  370. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Erin O'Toole, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-12-11
    Posted date: 2014-01-15
    Communication number: 371-312500 View associated registration

  371. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Julie Vaux, Chief of Staff | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-12-10
    Posted date: 2014-01-15
    Communication number: 371-312498 View associated registration

  372. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • George Da Pont, Deputy Minister | Health Canada (HC)
    • Luke Carter, Executive Advisor | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2013-12-05
    Posted date: 2014-01-15
    Communication number: 371-312497 View associated registration

  373. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Hélène Laverdière, Member of Parliament | House of Commons
    • Karl Bélanger, Principal Secretary | House of Commons
    • Rosa Kouri, Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-12-04
    Posted date: 2014-01-15
    Communication number: 371-312496 View associated registration

  374. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Idee Inyangudor, Director of Policy and Stakeholder Relations | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-12-02
    Posted date: 2014-01-15
    Communication number: 371-312495 View associated registration

  375. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rona Ambrose, Minister of Health | Health Canada (HC)
    • Graham Howell, Director of Strategic Planning | Health Canada (HC)
    • Chanel Savoie, Executive Assistant to the Minister | Health Canada (HC)
    • Scott Myers, Special Assistant - Policy, Office of the Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-12-02
    Posted date: 2014-01-15
    Communication number: 371-312493 View associated registration

  376. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alayna Johnson, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-11-14
    Posted date: 2013-12-15
    Communication number: 371-309557 View associated registration

  377. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-11-01
    Posted date: 2013-12-15
    Communication number: 371-309556 View associated registration

  378. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister of International Trade | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-11-01
    Posted date: 2013-12-15
    Communication number: 371-309555 View associated registration

  379. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Dewar, Member of Parliament | House of Commons
    • Hélène Laverdière, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-10-31
    Posted date: 2013-11-15
    Communication number: 371-303621 View associated registration

  380. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Graham Howell, Director of Strategic Planning | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2013-10-31
    Posted date: 2013-11-15
    Communication number: 371-303620 View associated registration

  381. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn McDade, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2013-10-31
    Posted date: 2013-11-15
    Communication number: 371-303619 View associated registration

  382. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn McDade, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2013-10-30
    Posted date: 2013-11-15
    Communication number: 371-303617 View associated registration

  383. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn McDade, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2013-10-29
    Posted date: 2013-11-15
    Communication number: 371-303614 View associated registration

  384. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn McDade, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2013-10-28
    Posted date: 2013-11-15
    Communication number: 371-303615 View associated registration

  385. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Cynthia Tran, Advisor, Stakeholder Relations & Outreach | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-10-24
    Posted date: 2013-11-15
    Communication number: 371-303612 View associated registration

  386. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health
    Communication date: 2013-10-16
    Posted date: 2013-11-15
    Communication number: 371-303610 View associated registration

  387. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Julie Vaux, Chief of Staff | Health Canada (HC)
    • Graham Howell, Director of Strategic Planning | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-10-10
    Posted date: 2013-11-15
    Communication number: 371-303609 View associated registration

  388. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jonathan Aitchison, Policy Advisor | Foreign Affairs, Trade and Development Canada
    • Matthew Senft, Policy Advisor | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-10-04
    Posted date: 2013-11-15
    Communication number: 371-303594 View associated registration

  389. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kathryn McDade, Asistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2013-10-03
    Posted date: 2013-11-15
    Communication number: 371-303593 View associated registration

  390. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Adam Taylor, Director of Communications and Forward Planning | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-10-01
    Posted date: 2013-11-15
    Communication number: 371-303591 View associated registration

  391. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gordon Venner, Assitant Deputy Minister | Foreign Affairs, Trade and Development Canada

    Subject Matter of the communication: Health, Industry
    Communication date: 2013-09-23
    Posted date: 2013-10-15
    Communication number: 371-296269 View associated registration

  392. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Marc Garneau, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-09-19
    Posted date: 2013-10-15
    Communication number: 371-296260 View associated registration

  393. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rona Ambrose, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2013-09-13
    Posted date: 2013-10-15
    Communication number: 371-296257 View associated registration

  394. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health
    Communication date: 2013-09-13
    Posted date: 2013-10-15
    Communication number: 371-296255 View associated registration

  395. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • James Nicholson, Director of Policy | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2013-09-03
    Posted date: 2013-10-15
    Communication number: 371-296252 View associated registration

  396. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rodger Cuzner, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2013-08-28
    Posted date: 2013-09-15
    Communication number: 371-290489 View associated registration

  397. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-07-18
    Posted date: 2013-08-15
    Communication number: 371-286589 View associated registration

  398. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jonathan Aitchison, Senior Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-07-10
    Posted date: 2013-08-15
    Communication number: 371-286590 (amended from 371-286569) View associated registration

  399. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Daniel King, Senior Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-07-10
    Posted date: 2013-08-15
    Communication number: 371-286570 View associated registration

  400. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Lise-Ann Jackson, Director Of Policy and Stakeholder Relations | Foreign Affairs and International Trade Canada (DFAITC)
    • Marisa Monnin, Policy Advisor | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-07-09
    Posted date: 2013-08-15
    Communication number: 371-286552 View associated registration

  401. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister of International Trade | Foreign Affairs and International Trade Canada (DFAITC)
    • Kirsten Hillman, Associate Assistant Deputy Minister | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-07-09
    Posted date: 2013-08-15
    Communication number: 371-286550 View associated registration

  402. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Libby Davies, Member of Parliament | House of Commons
    • Guy Caron, Member of Parliament | House of Commons
    • Carol Hughes, Member of Parliament | House of Commons
    • Karl Bélanger, Principal Secretary | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-06-11
    Posted date: 2013-07-15
    Communication number: 371-280405 View associated registration

  403. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Judith G. Seidman, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2013-06-04
    Posted date: 2013-07-15
    Communication number: 371-280404 View associated registration

  404. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2013-05-30
    Posted date: 2013-06-15
    Communication number: 371-277200 View associated registration

  405. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jasmine Brown, Policy Advisor | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-05-14
    Posted date: 2013-06-15
    Communication number: 371-277199 View associated registration

  406. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rosa Kouri, Parliamentary Affairs | House of Commons
    • Cédric Williams, Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-05-14
    Posted date: 2013-06-15
    Communication number: 371-277197 View associated registration

  407. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Dewar, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-05-10
    Posted date: 2013-06-15
    Communication number: 371-277195 View associated registration

  408. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Tim Norris, Director of Policy | Natural Resources Canada (NRCan)

    Subject Matter of the communication: Industry, Intellectual Property
    Communication date: 2013-05-09
    Posted date: 2013-06-15
    Communication number: 371-277193 View associated registration

  409. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gordon Venner, Assistant Deputy Minister | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: International Relations
    Communication date: 2013-05-08
    Posted date: 2013-06-15
    Communication number: 371-277191 View associated registration

  410. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rob Clarke, Member of Parliament | House of Commons
    • Gord Brown, Member of Parliament | House of Commons
    • Wladyslaw Lizon, Member of Parliament | House of Commons
    • Hedy Fry, Member of Parliament | House of Commons
    • Peter Stoffer, Member of Parliament | House of Commons
    • Karl Bélanger, Principal Secretary | House of Commons
    • Colin Carrie, Member of Parliament | House of Commons
    • Joy Smith, Member of Parliament | House of Commons
    • Carolyn Bennett, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2013-05-07
    Posted date: 2013-06-15
    Communication number: 371-277189 View associated registration

  411. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gordon Bown, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-05-02
    Posted date: 2013-06-15
    Communication number: 371-277180 View associated registration

  412. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jonathan Aitchison, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-04-26
    Posted date: 2013-05-15
    Communication number: 371-273005 View associated registration

  413. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry
    Communication date: 2013-04-24
    Posted date: 2013-05-15
    Communication number: 371-273002 View associated registration

  414. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Peter Braid, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2013-04-19
    Posted date: 2013-05-15
    Communication number: 371-272999 View associated registration

  415. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Douglas Smith, Chief of Staff | Human Resources and Skills Development Canada (HRSDC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-04-17
    Posted date: 2013-05-15
    Communication number: 371-272997 View associated registration

  416. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health
    Communication date: 2013-04-17
    Posted date: 2013-05-15
    Communication number: 371-272995 View associated registration

  417. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bruce Stanton, Assistant Deputy Chair of Committees of the Whole | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2013-04-16
    Posted date: 2013-05-15
    Communication number: 371-272994 View associated registration

  418. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Outhouse, Deputy Chief of Staff and Director, Communications | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2013-04-16
    Posted date: 2013-05-15
    Communication number: 371-272991 View associated registration

  419. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Dr. Rainer Engelhardt, Assistant Deputy Minister | Public Health Agency of Canada (PHAC)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2013-03-28
    Posted date: 2013-04-15
    Communication number: 371-268097 View associated registration

  420. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kennedy Stewart, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2013-03-28
    Posted date: 2013-04-15
    Communication number: 371-268096 View associated registration

  421. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Brad Lattanzi, Special Assistant | Industry Canada

    Subject Matter of the communication: Health, Industry, International Trade
    Communication date: 2013-03-27
    Posted date: 2013-04-15
    Communication number: 371-268094 View associated registration

  422. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Don Davies, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-03-26
    Posted date: 2013-04-15
    Communication number: 371-268073 View associated registration

  423. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Patrick Brown, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2013-03-25
    Posted date: 2013-04-15
    Communication number: 371-268092 View associated registration

  424. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-03-18
    Posted date: 2013-04-15
    Communication number: 371-268071 View associated registration

  425. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-03-01
    Posted date: 2013-04-15
    Communication number: 371-268068 View associated registration

  426. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property
    Communication date: 2013-02-20
    Posted date: 2013-03-15
    Communication number: 371-262929 View associated registration

  427. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister of International Trade | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2013-01-31
    Posted date: 2013-02-15
    Communication number: 371-258978 (amended from 371-258849) View associated registration

  428. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, International Trade
    Communication date: 2013-01-29
    Posted date: 2013-02-15
    Communication number: 371-258976 View associated registration

  429. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2012-12-14
    Posted date: 2013-01-15
    Communication number: 371-253530 View associated registration

  430. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bill Hawkins, Chief of Staff | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-12-14
    Posted date: 2013-01-15
    Communication number: 371-253529 View associated registration

  431. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • John Knubley, Deputy Minister | Industry Canada
    • Philip Jennings, A/Assistant Deputy Minister | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-11-02
    Posted date: 2012-12-15
    Communication number: 371-250353 View associated registration

  432. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-10-16
    Posted date: 2012-11-15
    Communication number: 371-244836 View associated registration

  433. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Lois Brown, Parliamentary Secretary | Canadian International Development Agency (CIDA)
    • Idee Inyangudor, Director of Policy | Canadian International Development Agency (CIDA)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-10-16
    Posted date: 2012-11-15
    Communication number: 371-244832 View associated registration

  434. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2012-10-16
    Posted date: 2012-11-15
    Communication number: 371-244830 View associated registration

  435. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Lois Brown, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-10-16
    Posted date: 2012-11-15
    Communication number: 371-244822 View associated registration

  436. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bruce Christie, Minister of Deputy Permanent Representative to the WTO | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-10-11
    Posted date: 2012-11-15
    Communication number: 371-244825 View associated registration

  437. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-10-04
    Posted date: 2012-11-15
    Communication number: 371-244818 View associated registration

  438. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Mauril Belanger, Member of Parliament | House of Commons
    • John McKay, Member of Parliament | House of Commons
    • Judy Foote, Member of Parliament | House of Commons
    • Peter Braid, Member of Parliament | House of Commons
    • Leon Benoit, Member of Parliament | House of Commons
    • Helene Laverdiere, Member of Parliament | House of Commons
    • Craig Scott, Member of Parliament | House of Commons
    • Bruce Hyer, Member of Parliament | House of Commons
    • Gord Brown, Member of Parliament | House of Commons
    • Francine Raynault, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-10-03
    Posted date: 2012-11-15
    Communication number: 371-244812 View associated registration

  439. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Libby Davies, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-10-01
    Posted date: 2012-11-15
    Communication number: 371-244810 View associated registration

  440. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Jason Kenney, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-09-28
    Posted date: 2012-10-15
    Communication number: 371-240763 View associated registration

  441. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Don Davies, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-09-27
    Posted date: 2012-10-15
    Communication number: 371-240762 View associated registration

  442. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Wayne Easter, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-09-26
    Posted date: 2012-10-15
    Communication number: 371-240760 View associated registration

  443. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Shuvaloy Majumdar, Senior Policy Advisor | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-09-21
    Posted date: 2012-10-15
    Communication number: 371-240758 View associated registration

  444. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Thomas Mulcair, Leader of the Opposition | House of Commons
    • Gauri Sreenivasan, Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-09-20
    Posted date: 2012-10-15
    Communication number: 371-240756 View associated registration

  445. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Christian Paradis, Minister of Industry | Industry Canada
    • Sean O'Leary, Policy Advisor | Industry Canada
    • Margaux Stastny, Communication Director | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-08-27
    Posted date: 2012-09-15
    Communication number: 371-236252 View associated registration

  446. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • John Baird, Minister of Foreign Affairs | Foreign Affairs and International Trade Canada (DFAITC)
    • Steven Farber, Senior Policy Advisor | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-08-20
    Posted date: 2012-09-15
    Communication number: 371-236251 View associated registration

  447. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-08-14
    Posted date: 2012-09-15
    Communication number: 371-236234 View associated registration

  448. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • John Anderson, Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-08-13
    Posted date: 2012-09-15
    Communication number: 371-236231 View associated registration

  449. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Douglas Smith, Chief of Staff | Human Resources and Skills Development Canada (HRSDC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-07-25
    Posted date: 2012-08-15
    Communication number: 371-232315 View associated registration

  450. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Howard Alper, Chair | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-07-24
    Posted date: 2012-08-15
    Communication number: 371-232314 View associated registration

  451. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Giguère, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-07-18
    Posted date: 2012-08-15
    Communication number: 371-232313 View associated registration

  452. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sandra Buckler, Chief of Staff | Health Canada (HC)
    • Leah Canning, Director of Policy | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-07-17
    Posted date: 2012-08-15
    Communication number: 371-232312 View associated registration

  453. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)
    • Jane E. Aubin, CSO/VP, Research and Knowledge Translation | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2012-07-13
    Posted date: 2012-08-15
    Communication number: 371-232311 View associated registration

  454. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Gauri Screenivasan, Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-07-11
    Posted date: 2012-10-10
    Communication number: 371-239990 (amended from 371-232309) View associated registration

  455. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Dr. Rainer Engelhardt, Assistant Deputy Minister | Public Health Agency of Canada (PHAC)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2012-06-28
    Posted date: 2012-07-15
    Communication number: 371-229847 View associated registration

  456. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Andrea van Vugt, Policy Advisor, Foreign Affairs, Trade and Intn'l Development | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-06-20
    Posted date: 2012-07-15
    Communication number: 371-229844 View associated registration

  457. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Steve Verheul, Chief Trade Negotiator (Canada-European Union) | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-06-20
    Posted date: 2012-07-15
    Communication number: 371-229842 View associated registration

  458. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kellie Leitch, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2012-06-15
    Posted date: 2012-07-15
    Communication number: 371-229837 View associated registration

  459. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Sean O'Leary, Policy Advisor | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-06-07
    Posted date: 2012-07-15
    Communication number: 371-229834 View associated registration

  460. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kelvin K. Ogilvie, Senator | Senate of Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-06-06
    Posted date: 2012-07-15
    Communication number: 371-229832 View associated registration

  461. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Peter MacKay, Member of Parliament | House of Commons
    • Lisa Raitt, Member of Parliament | House of Commons
    • Noël Kinsella, Honourable Senator | Senate of Canada
    • Janice Charette, Associate Secretary to the Cabinet & Deputy Minister (IGA) | Privy Council Office (PCO)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-06-06
    Posted date: 2012-07-15
    Communication number: 371-229814 View associated registration

  462. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2012-05-25
    Posted date: 2012-06-15
    Communication number: 371-226739 View associated registration

  463. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Robert Carberry, Assistant Secretary, Regulatory Cooperation Council Scretariat | Treasury Board Of Canada Secretariat (TBS)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2012-05-24
    Posted date: 2012-06-15
    Communication number: 371-226738 View associated registration

  464. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Ed Holder, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-05-17
    Posted date: 2012-06-15
    Communication number: 371-226737 View associated registration

  465. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Rob Merrifield, Member of Parliament | House of Commons

    Subject Matter of the communication: Industry, Intellectual Property, International Relations, International Trade
    Communication date: 2012-05-15
    Posted date: 2012-06-15
    Communication number: 371-226736 View associated registration

  466. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2012-05-10
    Posted date: 2012-06-15
    Communication number: 371-226735 View associated registration

  467. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Bernard Trottier, Member of Parliament | House of Commons
    • Lois Brown, Member of Parliament | House of Commons
    • John Anderson, Director of Parliamentary Affairs | House of Commons

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2012-04-27
    Posted date: 2012-05-15
    Communication number: 371-222807 View associated registration

  468. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2012-03-30
    Posted date: 2012-04-16
    Communication number: 371-217307 View associated registration

  469. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Kirsty Duncan, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Intellectual Property
    Communication date: 2012-03-28
    Posted date: 2012-04-16
    Communication number: 371-217288 View associated registration

  470. Innovative Medicines Canada
    In-house Organization
    Designated Public Office Holders who participated in the communication:
    • Paul Glover, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communica